Group leader
Research led by IBEC has analysed the antimicrobial activity of human histones against various bacteria, both in solution and in biofilm. The results are very promising and open the door to finding new, more effective treatments, particularly against Pseudomonas aeruginosa infections. This bacterium is mainly responsible for the development of chronic wounds and lung failure in patients with cystic fibrosis and other respiratory diseases.
IBEC will coordinate SPM4.0 and participate as a partner in ENTRY-DM, two of the projects selected in the 2023 call for PhD networks within the Marie Skłodowska-Curie Actions (MSCA). Thanks to these two projects, IBEC will add three new PhD students to its staff.
IBEC dedicates the 4th edition of its fundraising program, Faster Future, to develop novel strategies to treat infections and diseases caused by antibiotic-resistant bacteria. Specifically, the research seeks to fight … Read more
Chronic wounds are a challenge for microbiologists due to biofilms, complex structures where bacteria protect themselves from antibiotics, preventing infections from being treated effectively. A research team led by the … Read more
IBEC researchers have published a study in the journal Nature in which they have designed and developed a three-molecule complex that increases the efficacy and stability, while reducing the toxicity, … Read more
In a new study carried out by researchers from the Institute for Bioengineering of Catalonia (IBEC), improved so that they are more effective in much smaller doses, which opens the … Read more
Researchers at IBEC have developed a 3D model of the human intestine that simulates the characteristics of the intestinal mucosa and its reliefs. These mini-intestines will make it possible to … Read more
A new triple-acting antibiotic agent has managed to break through the biofilm extracellular matrix – a protective structure built by bacteria – and eliminate more than 50% of the pathogens … Read more
The group led by Eduard Torrents has succeeded in developing a triple-action antibiotic that breaks a protective structure produced by the bacteria themselves, the bacterial biofilm. Using this new antibiotic, … Read more
